PRAX - Praxis Precision Medicines, Inc.
IEX Last Trade
77.51
0.300 0.387%
Share volume: 2,940
Last Updated: Thu 26 Dec 2024 08:30:06 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$77.21
0.30
0.39%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
-0.41%
1 Month
-3.03%
3 Months
33.67%
6 Months
90.88%
1 Year
239.71%
2 Year
112.81%
Key data
Stock price
$77.51
DAY RANGE
$76.24 - $78.00
52 WEEK RANGE
$22.65 - $86.93
52 WEEK CHANGE
$260.81
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Marcio Souza
Region: US
Website: praxismedicines.com
Employees: 110
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: praxismedicines.com
Employees: 110
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression.
Recent news